Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease
Wellens J., Edmans M., Obolski U., McGregor CGC., Simmonds P., Turner M., Jarvis L., Skelley D., Dunachie S., Barnes E., Eyre D., Colombel J-F., Wong S-Y., Klenerman P., Lindsey J., Satsangi J., Thompson C.